GLPwatch

[LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE TREATMENT OF OBESITY].

Rev Med Liege · 2016

Last updated 2026-05-28

Liraglutide, already used to treat type 2 diabetes at doses of 1.2 or 1.8 mg, is now also approved at a 3.0 mg dose under the name Saxenda for treating obesity or overweight with related health issues. The higher dose works alongside diet and exercise, helping control appetite in addition to its effects on blood sugar. Clinical trials, including the SCALE studies, showed the 3.0 mg dose is both effective and safe for these patients.

AI summary of the abstract below.

JournalRev Med Liege, 2016
Citations3
Relative citation ratio0.11
NIH percentile8
Molecules liraglutide
Conditions studied Obesity

Abstract

Liraglutide is an analogue of Glucagon-Like Peptide-1 (GLP-1) already indicated under the trade name of Victoza for the treatment of type 2 diabetes, at usual doses of 1.2 or 1.8 mg as once daily subcutaneous injection. It is henceforth indicated at a dose of 3.0 mg, also as once daily subcutaneous injection, for the treatment of obesity or overweight with comorbidities under the trade name of Saxenda, in combination with diet and exercise. Besides a specific action on the endocrine pancreas, mainly responsible for the antihyperglycaemic effect, liraglutide helps controlling appetite at the hypothamalic level. A specific programme of controlled trials (especially SCALE studies) demonstrated both efficacy and safety of the 3.0 mg dose of liraglutide in obese or overweight patients with various comorbidities.

Verbatim abstract via PubMed 27337846 ↗

Related research